Better health.
Within reach.
Every day.



R&D Spotlight Series – Supporting Materials

Solid Orals

November 2026

hikma.

Disclaimer

Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma contained in this document may not have been audited and in some cases is based on management information and estimates.

No reliance may be placed for any purposes whatsoever on the information contained in this document or on its completeness. No representation or warranty, express or implied, is given by or on behalf of Hikma or its directors, officers or employees, advisors or any other person as to the accuracy or completeness of the information or opinions contained in this document and no liability whatsoever is accepted for any such information or opinions or any use which may be made of them.

Certain statements in this presentation, are forward-looking statements, including under the US federal securities laws, including the Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Any forward-looking statements made by or on behalf of Hikma speak only as of the date they are made and are based upon the knowledge and information available to the directors on the date of this presentation.

Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Hikma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak as only of the date of this presentation.

By participating in, listening to or accessing this document or by accepting any copy of this document, you agree to be bound by the foregoing limitations.

All names, logos, and trademarks are properties of their respective owners and are used for identification purposes only.

The Team



Hafrun Fridriksdottir

President, US and Chief R&D Officer

Role: Hafrun joined Hikma in April 2024 as President of Hikma Rx. In 2025, Hafrun took on additional responsibilities leading Hikma's new global R&D organisation and in February 2026, Hafrun was appointed as President, US, leading the Hikma Rx and commercial Injectables businesses in the US, in addition to her responsibilities as Global Head of R&D. Prior to joining Hikma, Hafrun held senior executive roles at leading global pharmaceutical companies including Alvotech, Teva Pharmaceuticals, Allergan and Actavis, and most recently has served in advisory and board roles for several biotech and mid-sized pharma companies.

Qualifications: MS Degree in Pharmacy and a PhD in Physical Pharmacy from the University of Iceland.



Jaber Qasem

Vice President; Solid Orals R&D

Role: Jaber joined Hikma in May 2022 as VP R&D MENA. In late 2022, Jaber took on additional responsibilities leading Hikma Chemicals and in November 2025, Jaber was appointed head of Global Solid Orals Development. Prior to joining Hikma, Jaber held senior roles at leading global pharmaceutical companies including Zydus Pharmaceutical, and Endo Pharmaceuticals.

Qualifications: MS Degree and a PhD in Pharmaceutical Sciences from the University of Kentucky.




Solid Orals

Jaber Qasem
Vice President; Solid Orals

Solid Orals: a global R&D network, centred in Amman

One platform across the US and MENA, with Centre of Excellence in Jordan

Hikma's global platform for developing and transferring oral solid products



200+
R&D specialists

7
Countries with R&D or Technology Transfer teams


Oral forms drive the US and EU loss of exclusivity opportunity

Oral solids represent 88% of US non-injectable LOE value; oral forms are 72% of the EU total

US Rx: LOE by dosage form, non-injectables ($bn)[1]



EU (ex-biologics): LOE by pharmaceutical form ($bn)[2]



[1] Value = brand gross sales losing exclusivity; Hikma internal assessment based on IQVIA, IPD and Evaluate. Excludes 2026 LOEs ($6.0b) and injectables; 2037+ aggregates all LOEs from 2037 onward.

[2] Values from IQVIA. LOE dates based on IPD assessment and Hikma analysis. Excludes all Biologics.

Solid Orals: 140+ projects, and 50+ filings targeted for 2026

Development is consolidating in Amman, with complexity and co-development rising across the portfolio

Majority of upcoming LOE opportunities are oral solids


140+
active projects across global markets

50+
new filings targeted in 2026

~40%
of the portfolio is complex and/or differentiated today

- Shifting majority of development to Amman, Jordan
- Differentiating through technologies – extended and modified release to **increase complexity** and limit competition
- Increasingly **pursuing co-development opportunities** between MENA and US to optimise resource utilisation and improve efficiency

Portfolio complexity under development



Case studies: Hikma's technology edge on two complex oral products

Project A builds on injectables know-how; Project B relies on in-house process innovation

Project A: oral neurology therapy

WHAT IT IS

Oral tablet for a chronic neurological condition, historically available only as an injectable

LAUNCH POSITION

Launched in 2026, first-to-market in MENA

Why Hikma is positioned to win

1 Specialised formulation: cyclodextrin complexation

Home grown know-how in solids

2 Specialised manufacturing: lyophilisation

Complex freeze-dried, a step typical of injectables. Hikma has the capability

3 Clinical bioequivalence: patient-based study

Needs a clinical study in patients; in-house capability

Injectables heritage helped inform new formulation and manufacturing

Project B: oral oncology therapy

WHAT IT IS

Oral oncology tablet; US patent expiry expected in 2027, 2033

LAUNCH POSITION

Launched in 2026, first-to-market in MENA. FDA tentative approval received on the US filing; settlement date 2029

Why Hikma is positioned to win

1 Hot melt extrusion (HME): solvent-free process

First HME machine at Hikma

2 Cryogenic pin milling: first of its kind

Uses liquid nitrogen in the milling step; a differentiated process that competitors may find hard to replicate

3 Sustainability: lower environmental footprint

Solvent-free HME reduces footprint vs solvent-based processes

Technically innovative solution to environmental need while providing differentiation & lower COGs



Thank you.